Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly Makes Big Biologics Play For Alzheimer’s

This article was originally published in The Pink Sheet Daily

Executive Summary

But study published in Lancet raises questions about efficacy of anti-amyloid therapy.

You may also be interested in...



FDA, Pharma Need To Take Next Step In Alzheimer’s Imaging Tools

Even with consensus on a path forward for imaging agents to be validated for detection of amyloid-beta, there are still questions about the clinical utility of the agents and the potential path toward their use in diagnosis of, or prognosis for, Alzheimer's disease

FDA, Pharma Need To Take Next Step In Alzheimer’s Imaging Tools

Even with consensus on a path forward for imaging agents to be validated for detection of amyloid-beta, there are still questions about the clinical utility of the agents and the potential path toward their use in diagnosis of, or prognosis for, Alzheimer's disease

Start-Up Archer Preps Alzheimer’s Drugs For Phase I

IND filed, company aims to use nilvadipine derivative against soluble amyloid.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068177

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel